Design Therapeutics, Inc.
DSGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $15 | $0 | $0 | $0 |
| Gross Profit | -$15 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $16 | $15 | $12 |
| G&A Expenses | $5 | $6 | $5 | $5 |
| SG&A Expenses | $5 | $6 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$15 | -$0 | $0 | $0 |
| Operating Expenses | $5 | $21 | $20 | $17 |
| Operating Income | -$19 | -$22 | -$20 | -$17 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | $3 |
| Pre-Tax Income | -$17 | -$19 | -$18 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$19 | -$18 | -$14 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.34 | -0.31 | -0.24 |
| % Growth | 11.8% | -9.7% | -29.2% | – |
| EPS Diluted | -0.3 | -0.34 | -0.31 | -0.24 |
| Weighted Avg Shares Out | 57 | 57 | 57 | 57 |
| Weighted Avg Shares Out Dil | 57 | 57 | 57 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $3 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$19 | -$20 | -$17 |
| % Margin | – | – | – | – |